-
Her2-negative Breast Cancer Market Report 2032: Epidemiology, Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight
27 Mar 2024 11:32 GMT
… Receptor 1 gene (ESR1)-mutated advanced or metastatic breast cancer. This approval … Receptor 1 gene (ESR1). The approval is for individuals whose cancer has … patent details, and other information for emerging therapies.
Her2-negative Breast Cancer …
-
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
25 Mar 2024 12:30 GMT
… company dedicated to pioneering innovative cancer and viral infection treatments, announces … safely intravenously (i.v.). Indaptus’ patented technology is composed of single … (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The …
-
GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare
25 Mar 2024 12:00 GMT
… breast or ovarian cancer were in genes other than BRCA1… Saliva Test: geneType’s patented non-invasive saliva test … Technologies Limited (ASX: GENE; Nasdaq: GENE) is a diversified molecular … and EasyDNA brands. GENE offers cancer predictive testing and …
-
FDA Updates for Week of March 18, 2024: A $4.25 Million Gene Therapy and Drugs for Duchenne and Leukemia
23 Mar 2024 16:42 GMT
… cost of its newly approved gene therapy, Lenmeldy (atidarsagene autotemcel … is the first approved gene therapy to treat children … lymphoma, T-cells become cancerous and presents as red, … subcutaneous administration. It has patent protection through 2037 for …
-
Bayer’s Prostate Cancer Drug Nubeqa on Track to Generate Blockbuster Sales in...
22 Mar 2024 16:09 GMT
…
Bayer hailed its prostate cancer drug Nubeqa (darolutamide) … metastatic hormone sensitive prostate cancer. Bayer selected progression-free … by the European Patent Office secured one patent into 2026.
… Bayer also has cell and gene therapies due to the …
-
AnGes files patent for crispr-based method for modifying mutant lRRK2 gene in cells
22 Mar 2024 14:59 GMT
… , NSAID cancer drugs was a key innovation area identified from patents. AnGes … ;threonine-protein kinase 2 (LRRK2) gene associated with monogenic Parkinson… in the LRRK2 gene, potentially excising specific exons. The patent application aims …
-
Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection
28 Mar 2024 13:58 GMT
… knockdown (≥70%) of the target genes (ACE2 and TMPRSS2) at … .
Disclosure
VY has a patent Covid-19 Trap Technology pending … 1 (SAT1)-A potential gene target for selective sensitization of … lipid nanoparticle to deliver siRNA. Cancers. 2022;14:5179. doi: …
-
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
28 Mar 2024 13:00 GMT
… and gene therapies into potential cures for difficult-to-treat cancers … therapies across multiple cancers, as well as lentiviral gene therapies for severe … under development; government regulation; patent and intellectual property matters; competition …
-
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
28 Mar 2024 12:00 GMT
… dedicated to pioneering innovative cancer and viral infection treatments, … revolutionize the treatment of cancer and viral infections.”
Mr … (i.v.). Indaptus’ patented technology is composed of … ) and Stimulator of interferon genes (STING) agonist Decoy platform …
-
BrocElite Plus Reviews (2024) Know ALL the Facts Before Buy
27 Mar 2024 16:29 GMT
… ’s natural detoxification processes – including gene expression and liver functions linked … with scientists to develop a patented process for creating 100% natural … against chemical carcinogens.” Carcinogens are cancer-causing compounds, and broccoli sprout …